5th PREDiCT: 3D Oncology & Tissue Models Summit – The community of industry leading preclinical 3D model developers will once again gather this September to accelerate benchtop to bedside through complex preclinical 3D model adoption: From mechanistic disease modeling to boosting clinical relevancy and translational outcomes.
The 5th edition of this meeting will be held digitally on September 30 – October 1st, gathering 150+ leaders from across pharma, biotechs, regulatory agencies and academia. This year, we’ll be honing in on overcoming the current challenges we face, such as:
- The cost and time requirements to develop a specific model
- The advancements of using 3D models to support drug discovery, ADME and safety studies
- Functionality and complexity of multi-organ 3D models, micro-fluid system, assay developments and bioprinting
- Regulatory agencies’ expectation and data requirement
Access your copy of the Full Event Guide
WHY SHOULD YOU ATTEND?
3D models for preclinical studies are no longer a dream but turning into a reality for scientists to give much better representation and translatable results for drug candidates before proceeding to clinic.
While only a few major pharma companies have been committed to 3D model utilization over the last 4 years, successes from Vertex, J&J, GSK, and breakthroughs from technology platforms such as Draper and MIMETAS (both are attending the meeting as official 2020 Partners) have instilled greater confidence to the wide life science world.
The industry has now arrived at the tipping point that by perfecting complex 3D models’ technologies, and truly applying these into daily experiments, we will be able to improve our clinical relevancy of safety and efficacy.
The 5th edition of the PREDiCT: 3D Oncology & Tissue Models Summit will once again re-unite industry leaders to discuss, reveal and share how to accelerate 3D platforms to enable better prediction of drug development’s success – increasing clinical relevancy and boosting efficacy and translatability for innovative pipeline.
We’ll be discussing the pros, cons, learnings from industry leaders, challenges, and more, on all of the hottest 3D models:
- Organoids
- Multi-organ systems
- Multi-cellular systems
- Microphysiological systems
- Lab/ Organ-on-chips
The world-class speaker faculty includes:
- Terry Van Vleet, Head of Investigative Toxicology, Pathology, Molecular & Computational Toxicology, Abbvie
- Szczepan Baran, Head of Emerging Technologies, Novartis
- Suzanne Fitzpatrick, Senior Advisor for Toxicology Center for Food Safety and Applied Nutrition, S Food and Drug Administration (FDA)
- MinJae Song, Staff Scientist – 3D Bioprinting Core, National Institute of Health Sciences
- Niresh Hariparsad, Director – Drug Metabolism & Pharmacokinetics Project Leader, Vertex Pharmaceuticals
- Jason Ekert, Senior Director & Head of Complex In Vitro Models, GlaxoSmithKline
- Linda Lieberman, Principal Scientist, Merck & Co
And many more. View the Full Event Guide here for the complete expert speaker faculty and cutting-edge agenda.
Attendance is completely free for drug developers, researchers and academics! You can register your guest past here.
T&Cs Apply:
- All bookings under the Pharma, Biotech & Academics category are subject to organizer approval.
- Solution Provider Rates apply to all companies who offer any kind of modelling solution.